Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) EBITDA: 2010-2025

Historic EBITDA for Niagen Bioscience (NAGE) over the last 14 years, with Sep 2025 value amounting to $4.2 million.

  • Niagen Bioscience's EBITDA rose 164.42% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 million, marking a year-over-year increase of 4218.57%. This contributed to the annual value of $7.7 million for FY2024, which is 237.99% up from last year.
  • Per Niagen Bioscience's latest filing, its EBITDA stood at $4.2 million for Q3 2025, which was up 33.00% from $3.2 million recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's EBITDA peaked at $7.1 million during Q4 2024, and registered a low of -$8.8 million during Q3 2021.
  • Over the past 3 years, Niagen Bioscience's median EBITDA value was -$168,000 (recorded in 2023), while the average stood at $1.3 million.
  • As far as peak fluctuations go, Niagen Bioscience's EBITDA plummeted by 110.70% in 2021, and later skyrocketed by 4,332.74% in 2024.
  • Quarterly analysis of 5 years shows Niagen Bioscience's EBITDA stood at -$5.3 million in 2021, then spiked by 72.84% to -$1.4 million in 2022, then spiked by 88.37% to -$168,000 in 2023, then surged by 4,332.74% to $7.1 million in 2024, then spiked by 164.42% to $4.2 million in 2025.
  • Its EBITDA was $4.2 million in Q3 2025, compared to $3.2 million in Q2 2025 and $4.8 million in Q1 2025.